June 25, 2020

EAQ172 Available Through ECOG-ACRIN Cancer Research Group: Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis

RecommendThanks for recommending this page!

The page you recommended will be added to the "what others are reading" feed on "My ACR".

 BookmarkThanks for bookmarking this page!

The page you bookmarked will be added to the "my reading list" feed on "My ACR".

ECOG-ACRIN activated a Symptom Science protocol (EAQ172) looking at assessing pneumonitis response to additional immunosuppression in patients with steroid-refractory pneumonitis at 28-days. This study includes radiographic and correlative biospecimen response research aims. EAQ172: Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis.

Continue reading